FDA Grants Accelerated Approval to Replimune’s Onco-Viral Therapy Tudriqev in Combination with Nivolumab for Advanced Melanoma, Offering New Treatment Option

August 17, 2026

U.S. Food and Drug Administration USA

Overview

The U.S. FDA granted accelerated approval to Replimune, Inc.’s oncolytic viral therapy Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adult patients with advanced cutaneous melanoma who progressed on PD-1 inhibitor-based therapy. Tudriqev, also holding Breakthrough Therapy and Priority Review designations, demonstrated objective responses with an approximate 14-month duration of response in treatment-resistant patients. This approval provides a crucial new therapeutic option for patients with difficult-to-treat advanced melanoma.

In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Replimune’s genetically modified oncolytic viral therapy, Tudriqev (vusolimogene oderparepvec-wtpg), in combination with nivolumab, for adult patients with advanced cutaneous melanoma whose disease progressed after PD-1 inhibitor-based therapy. Tudriqev also received Breakthrough Therapy and Priority Review designations. The combination therapy was recognized for achieving objective responses with a duration of response of approximately 14 months in treatment-resistant patients. This marks a groundbreaking therapeutic option for patients with challenging advanced melanoma, addressing a significant unmet medical need.

Technical / Clinical Details

Tudriqev is a herpes simplex virus type 1 (HSV-1)-based oncolytic virus genetically modified to replicate within tumor cells and express immune-stimulating proteins. This virus is designed to specifically lyse tumor cells while simultaneously activating an anti-tumor immune response. Nivolumab, a PD-1 inhibiting antibody, is expected to synergistically enhance the anti-tumor effect by releasing immune suppression in the tumor microenvironment when combined with Tudriqev. Clinical trials confirmed an objective response rate (ORR) in a patient population resistant to PD-1 inhibitors, with a median duration of response (DoR) of approximately 14 months. The safety profile was manageable, offering new hope for patients for whom traditional treatments have been challenging.

Background & Context

Melanoma is the most lethal type of skin cancer, and advanced forms often carry a poor prognosis. While immune checkpoint inhibitors, such as PD-1 inhibitors, have become central to treatment in recent years, a subset of patients exhibits resistance, necessitating urgent new therapeutic options. Oncolytic viral therapies, with their dual mechanism of directly destroying tumor cells and inducing systemic anti-tumor immunity, have shown great promise in combination with immune checkpoint inhibitors. This accelerated approval by the FDA represents a significant advancement in the therapeutic strategy for this field, showcasing the potential for novel combination approaches.

Strategic Significance & Outlook

The accelerated approval of Tudriqev in combination with nivolumab has the potential to improve survival and quality of life for patients with treatment-resistant advanced melanoma. As an accelerated approval, further confirmatory trials will be required, but this success is expected to accelerate further research and development of combination therapies involving oncolytic viruses and immune checkpoint inhibitors. The potential application of this approach to other solid tumors is also being explored. Tudriqev’s Breakthrough Therapy designation indicates its high potential therapeutic benefit, with expectations for its inclusion in future treatment guidelines and broader patient access, thereby transforming the landscape of advanced cancer care.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.